Texas Ebola patient gets experimental drug

2014-10-07 07:03
Texas Health Presbyterian Hospital. (AP)

Texas Health Presbyterian Hospital. (AP)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Washington - A Liberian man diagnosed with Ebola in Texas has received an experimental drug, the first time the medicine has been used to fight the deadly virus in humans, officials said on Monday.

Thomas Eric Duncan is in critical but stable condition, Texas Health spokesperson Candace White said in a brief statement to reporters.

"He is now receiving an investigational medication, brincidofovir," she said.

The drug is made by the North Carolina-based pharmaceutical company Chimerix.

Brincidofovir is currently in phase three trials against cytomegalovirus (CMV) and adenovirus, the company said on its website.

However, for Ebola infections it has only been evaluated in test-tubes, not animals or humans, it added.

The drug "works by keeping viruses from creating additional copies of themselves", Chimerix said.

Three American missionaries who were treated for Ebola in the United States after they became infected in Liberia were given other experimental treatments.

The supply of one promising drug, ZMapp, has run out.

US doctor Rick Sacra was treated with the Canadian firm Tekmira's Ebola drug, TKM-Ebola, as well as serum from doctor Kent Brantly, who had Ebola and recovered.

There is no market-approved drug for treating Ebola yet, and no vaccine to prevent it.

Duncan is the first person to be diagnosed with Ebola in the United States, and is believed to have become infected while in Liberia.

His condition worsened from serious to critical over the weekend.

West Africa is currently battling the largest outbreak of Ebola in history, with more than 3 300 dead from the haemorrhagic virus since the start of the year.

Read more on:    us  |  ebola

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.